The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...
Accurate measurement of HMGB-1, neopterin and sIL-2R supports reliable assessment of immune activation across clinical and ...
Recent advances in biomedical technologies—including microphysiological systems (MPS), humanized and chimeric animal models, nanomaterials, cell-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results